Etanercept biosimilar - LG Chem
Alternative Names: Eucept; LBEC-0101; TNFceptLatest Information Update: 17 Nov 2021
At a glance
- Originator LG Life Sciences
- Developer LG Chem; Mochida Pharmaceutical
- Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Disease-modifying antirheumatics; Recombinant fusion proteins; Skin disorder therapies
- Mechanism of Action Immunosuppressants; Tumour necrosis factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Ankylosing spondylitis; Juvenile rheumatoid arthritis; Non-radiographic axial spondyloarthritis; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis
Most Recent Events
- 27 Sep 2021 Launched for Ankylosing spondylitis in South Korea (SC) as of September 2021 (LG Chem pipeline, September 2021)
- 27 Sep 2021 Launched for Juvenile rheumatoid arthritis (In adolescents, In children) in South Korea (SC) as of September 2021 (LG Chem pipeline, September 2021)
- 27 Sep 2021 Launched for Non-radiographic axial spondyloarthritis in South Korea (SC) as of September 2021 (LG Chem pipeline, September 2021)